Partial-EMT in oral squamous cell carcinoma: molecular circuitry and clinical translation

Abstract

Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with high morbidity and mortality. Globally, about 400 000 people are affected, often with a poor quality of life. Its high mortality is mainly due to its aggressive growth and tendency to spread. Epithelial-mesenchymal transition (EMT) is a central regulatory hub driving tumor cell migration and invasion by enabling changes in cell characteristics. During EMT, epithelial cells gradually take on mesenchymal traits, gaining mobility and spreading more easily. Recent multi-omics studies show that many cancer cells exist in a hybrid or partial-EMT state, which lies between the full epithelial and mesenchymal forms. Cells in this state are especially invasive and metastatic, with high plasticity that promotes tumor progression. This review summarizes the role of partial-EMT in OSCC, with a focus on how it alters the tumor microenvironment (TME), promotes invasion and metastasis, and influences cancer stem cells (CSCs). We also highlight the link between partial-EMT and treatment resistance in OSCC. Based on these insights, we discuss therapeutic strategies targeting partial-EMT to improve outcomes. Targeting partial-EMT may offer promising strategies to enhance treatment effectiveness and improve patient survival and quality of life.

References

[1] Tan Yet al.. Oral squamous cell carcinomas: state of the field and emerging directions. Int. J. Oral. Sci., 2023, 15: 44

[2] Chamoli Aet al.. Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics. Oral. Oncol., 2021, 121: 105451

[3] Katirachi SK, Grønlund MP, Jakobsen KK, Grønhøj C, Von Buchwald C. The prevalence of HPV in oral cavity squamous cell carcinoma. Viruses, 2023, 15: 451

[4] Dey Set al.. Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention. Med. Oncol., 2022, 39 30

[5] Meng Xet al.. The role of non-coding RNAs in drug resistance of oral squamous cell carcinoma and therapeutic potential. Cancer Commun., 2021, 41: 981-1006

[6] Marles H, Biddle A. Cancer stem cell plasticity and its implications in the development of new clinical approaches for oral squamous cell carcinoma. Biochem. Pharmacol., 2022, 204: 115212

[7] Bakir B, Chiarella AM, Pitarresi JR, Rustgi AK. EMT, MET, plasticity, and tumor metastasis. Trends Cell Biol., 2020, 30: 764-776

[8] Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J. Hematol. Oncol., 2022, 15: 129

[9] Akhmetkaliyev A, Alibrahim N, Shafiee D, Tulchinsky E. EMT/MET plasticity in cancer and Go-or-Grow decisions in quiescence: the two sides of the same coin?. Mol. Cancer, 2023, 22 90

[10] Pal A, Barrett TF, Paolini R, Parikh A, Puram SV. Partial EMT in head and neck cancer biology: a spectrum instead of a switch. Oncogene, 2021, 40: 5049-5065

[11] Saitoh M. Transcriptional regulation of EMT transcription factors in cancer. Semin. Cancer Biol., 2023, 97: 21-29

[12] Li Det al.. Heterogeneity and plasticity of epithelial-mesenchymal transition (EMT) in cancer metastasis: Focusing on partial EMT and regulatory mechanisms. Cell Prolif., 2023, 56 e13423

[13] Kisoda Set al.. The role of partial-EMT in the progression of head and neck squamous cell carcinoma. J. Oral. Biosci., 2022, 64: 176-182

[14] Liao Cet al.. Partial EMT in squamous cell carcinoma: a snapshot. Int. J. Biol. Sci., 2021, 17: 3036-3047

[15] Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J., 2021, 40: e108647

[16] Muralidharan Set al.. PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas. Curr. Oncol., 2022, 29: 8285-8301

[17] Luo K. Signaling cross talk between TGF-β/Smad and other signaling pathways. Cold Spring Harb. Perspect. Biol., 2017, 9: a022137

[18] Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425: 577-584

[19] Horta, C. A., Doan, K. & Yang, J. Mechanotransduction pathways in regulating epithelial-mesenchymal plasticity. Curr. Opin. Cell Biol. 85, 102245 (2023).

[20] Scott KE, Fraley SI, Rangamani P. A spatial model of YAP/TAZ signaling reveals how stiffness, dimensionality, and shape contribute to emergent outcomes. Proc. Natl. Acad. Sci. USA, 2021, 118 e2021571118

[21] Tam SY, Wu VWC, Law HKW. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond. Front. Oncol., 2020, 10: 486

[22] Haerinck J, Berx G. Partial EMT takes the lead in cancer metastasis. Dev. Cell., 2021, 56: 3174-3176

[23] Park PHet al.. Partial-EMT cell state correlates with single cell pattern of invasion in head and neck SCC keratinocytes. J. Pathol., 2025, 267: 92-104

[24] Knutsen Eet al.. Identification of a core EMT signature that separates basal-like breast cancers into partial- and post-EMT subtypes. Front. Oncol., 2023, 13: 1249895

[25] Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov., 2021, 11: 933-959

[26] Li Z, Yin P. Tumor microenvironment diversity and plasticity in cancer multidrug resistance. BBA-Rev. Cancer, 2023, 1878: 188997

[27] Saxena K, Jolly MK, Balamurugan K. Hypoxia, partial EMT and collective migration: emerging culprits in metastasis. Transl. Oncol., 2020, 13: 100845

[28] Dong Let al.. SPP1+ TAM regulates the metastatic colonization of CXCR4+ metastasis-associated tumor cells by remodeling the lymph node microenvironment. Adv. Sci., 2024, 11 e2400524

[29] Song Het al.. Single-cell transcriptome analysis reveals changes of tumor immune microenvironment in oral squamous cell carcinoma after chemotherapy. Front. Cell Dev. Biol., 2022, 10: 914120

[30] Bednarczyk RBet al.. Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer. Oncotarget, 2018, 9: 24272-24282

[31] Lin Y, Qi Y, Jiang M, Huang W, Li B. Lactic acid-induced M2-like macrophages facilitate tumor cell migration and invasion via the GPNMB/CD44 axis in oral squamous cell carcinoma. Int. Immunopharmacol., 2023, 124: 110972

[32] Cao Y, Zhou Z, He S, Liu W. TTYH3 promotes the malignant progression of oral squamous cell carcinoma SCC-9 cells by regulating tumor-associated macrophage polarization. Arch. Oral. Biol., 2024, 165: 106028

[33] Jiang Det al.. Single-cell profiling reveals conserved differentiation and partial EMT programs orchestrating ecosystem-level antagonisms in head and neck cancer. J. Cell. Mol. Med., 2025, 29 e70575

[34] Li E, Cheung HCZ, Ma S. CTHRC1+ fibroblasts and SPP1+ macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma. Sci. Rep., 2024, 14 17412

[35] Qu Yet al.. TAMs-derived SPP1, regulated by HIF-1α/STAT3 signaling pathway, influences colorectal cancer malignant progression by activation of EMT via integrin αvβ3. Int. Immunopharmacol., 2025, 159: 114947

[36] Papadaki MAet al.. Epithelial-to-mesenchymal transition heterogeneity of circulating tumor cells and their correlation with MDSCs and Tregs in HER2-negative metastatic breast cancer patients. Anticancer Res., 2021, 41: 661-670

[37] Li Yet al.. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Gastroenterology, 2014, 146: 1701-1713.e1709

[38] Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 2003, 3: 721-732

[39] Singh M, Mukundan S, Jaramillo M, Oesterreich S, Sant S. Three-dimensional breast cancer models mimic hallmarks of size-induced tumor progression. Cancer Res., 2016, 76: 3732-3743

[40] Singh Met al.. Controlled three-dimensional tumor microenvironments recapitulate phenotypic features and differential drug response in early vs advanced stage breast cancer. ACS Biomater. Sci. Eng., 2018, 4: 421-431

[41] Ko CC, Yang P-M. Hypoxia-induced MIR31HG expression promotes partial EMT and basal-like phenotype in pancreatic ductal adenocarcinoma based on data mining and experimental analyses. J. Transl. Med., 2025, 23 305

[42] Li Xet al.. circFNDC3B Accelerates Vasculature formation and metastasis in oral squamous cell carcinoma. Cancer Res., 2023, 83: 1459-1475

[43] Norgard RJet al.. Calcium signaling induces a partial EMT. EMBO Rep., 2021, 22 e51872

[44] Sun Yet al.. Restoring BARX2 in OSCC reverses partial EMT and suppresses metastasis through miR-186-5p/miR-378a-3p-dependent SERPINE2 inhibition. Oncogene, 2024, 43: 1941-1954

[45] Karaosmanoğlu O, Banerjee S, Sivas H. Identification of biomarkers associated with partial epithelial to mesenchymal transition in the secretome of slug over-expressing hepatocellular carcinoma cells. Cell Oncol., 2018, 41: 439-453

[46] Giannelli G, Bergamini C, Fransvea E, Sgarra C, Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology, 2005, 129: 1375-1383

[47] Kim SKet al.. Phenotypic heterogeneity and plasticity of cancer cell migration in a pancreatic tumor three-dimensional culture model. Cancers, 2020, 12: 1305

[48] Chaturvedi V, Fournier-Level A, Cooper HM, Murray MJ. Loss of Neogenin1 in human colorectal carcinoma cells causes a partial EMT and wound-healing response. Sci. Rep., 2019, 9 4110

[49] Wu JSet al.. Cathepsin B defines leader cells during the collective invasion of salivary adenoid cystic carcinoma. Int. J. Oncol., 2019, 54: 1233-1244

[50] Zhi Yet al.. Spatial transcriptomic and metabolomic landscapes of oral submucous fibrosis-derived oral squamous cell carcinoma and its tumor microenvironment. Adv. Sci., 2024, 11 e2306515

[51] Liu YTet al.. Immune-featured stromal niches associate with response to neoadjuvant immunotherapy in oral squamous cell carcinoma. Cell Rep. Med., 2025, 6: 102024

[52] Zhao Set al.. INHBA+ macrophages and Pro-inflammatory CAFs are associated with distinctive immunosuppressive tumor microenvironment in submucous Fibrosis-Derived oral squamous cell carcinoma. BMC Cancer, 2025, 25 857

[53] Sutera S, Furchì OA, Pentenero M. Exploring cancer-associated fibroblasts in OSCC and OPMDs: microenvironment insights. scoping review. Oral. Dis., 2025, 31: 1982-1990

[54] Ren Fet al.. Myeloid cell-derived apCAFs promote HNSCC progression by regulating proportion of CD4+ and CD8+ T cells. J. Exp. Clin. Cancer Res., 2025, 44: 33

[55] Shan Tet al.. Prometastatic mechanisms of CAF-mediated EMT regulation in pancreatic cancer cells. Int. J. Oncol., 2017, 50: 121-128

[56] Huynh NCN, Huang TT, Nguyen CTK, Lin FK. Comprehensive integrated single-cell whole transcriptome analysis revealed the p-EMT tumor cells-CAFs communication in oral squamous cell carcinoma. Int. J. Mol. Sci., 2022, 23: 6470

[57] Mosa MHet al.. A Wnt-induced phenotypic switch in cancer-associated fibroblasts inhibits EMT in colorectal cancer. Cancer Res., 2020, 80: 5569-5582

[58] Liu Yet al.. Identification of prognostic biomarkers originating from the tumor stroma of betel quid-associated oral cancer tissues. Front. Oncol., 2021, 11: 769665

[59] Liu Xet al.. LOX+ iCAFs in HNSCC have the potential to predict prognosis and immunotherapy responses revealed by single cell RNA sequencing analysis. Sci. Rep., 2025, 15 7028

[60] Punovuori Ket al.. Multiparameter imaging reveals clinically relevant cancer cell-stroma interaction dynamics in head and neck cancer. Cell, 2024, 187: 7267-7284.e7220

[61] Strating Eet al.. Co-cultures of colon cancer cells and cancer-associated fibroblasts recapitulate the aggressive features of mesenchymal-like colon cancer. Front. Immunol., 2023, 14: 1053920

[62] Yang Y, Zheng H, Zhan Y, Fan S. An emerging tumor invasion mechanism about the collective cell migration. Am. J. Transl. Res., 2019, 11: 5301-5312

[63] Cheung KJ, Ewald AJ. A collective route to metastasis: seeding by tumor cell clusters. Science, 2016, 352: 167-169

[64] Hsiao SYet al.. MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition. J. Exp. Clin. Cancer Res., 2023, 42: 40

[65] Daugaard Iet al.. miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells. Oncogenesis, 2017, 6 e366

[66] Li CFet al.. Snail-induced claudin-11 prompts collective migration for tumour progression. Nat. Cell Biol., 2019, 21: 251-262

[67] Gao J, Zhu Y, Nilsson M, Sundfeldt K. TGF-β isoforms induce EMT independent migration of ovarian cancer cells. Cancer Cell Int., 2014, 14 72

[68] Kariya Y, Oyama M, Suzuki T, Kariya Y. vβ3 Integrin induces partial EMT independent of TGF-β signaling. Commun. Biol., 2021, 4: 490

[69] Chiba Tet al.. Transforming growth factor-β1 suppresses bone morphogenetic protein-2-induced mesenchymal-epithelial transition in HSC-4 human oral squamous cell carcinoma cells via Smad1/5/9 pathway suppression. Oncol. Rep., 2017, 37: 713-720

[70] Rypens Cet al.. Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Res. Treat., 2020, 180: 385-395

[71] Teng YHet al.. TGF-β signaling redirects Sox11 gene regulatory activity to promote partial EMT and collective invasion of oncogenically transformed intestinal organoids. Oncogenesis, 2025, 14 17

[72] Vanini JVet al.. Epithelial-mesenchymal transition related to bone invasion in oral squamous cell carcinoma. J. Bone Oncol., 2022, 33: 100418

[73] Fan Let al.. Foxhead box D1 promotes the partial epithelial-to-mesenchymal transition of laryngeal squamous cell carcinoma cells via transcriptionally activating the expression of zinc finger protein 532. Bioengineered, 2022, 13: 3057-3069

[74] Ourailidis Iet al.. Multi-omics analysis to uncover the molecular basis of tumor budding in head and neck squamous cell carcinoma. npj Precis. Oncol., 2025, 9 73

[75] Xiang Z, He Q, Huang L, Xiong B, Xiang Q. Breast cancer classification based on tumor budding and stem cell-related signatures facilitate prognosis evaluation. Front. Oncol., 2021, 11: 818869

[76] Pavlič Aet al.. Tumour budding and poorly differentiated clusters in colon cancer - different manifestations of partial epithelial-mesenchymal transition. J. Pathol., 2022, 258: 278-288

[77] Aban CEet al.. Downregulation of E-cadherin in pluripotent stem cells triggers partial EMT. Sci. Rep., 2021, 11 2048

[78] Wang Wet al.. CYTOR facilitates formation of FOSL1 phase separation and super enhancers to drive metastasis of tumor budding cells in head and neck squamous cell carcinoma. Adv. Sci., 2024, 11 e2305002

[79] Omae Tet al.. Mechanism of tumor budding in patient-derived metachronous oral primary squamous cell carcinoma cell lines. Int. J. Mol. Sci., 2025, 26: 3347

[80] Yadav K, Singh T, Varma K, Bhargava M, Misra V. Evaluation of tumor budding and its correlation with histomorphological prognostic markers in oral squamous cell carcinoma and its association with the epithelial-mesenchymal transition process. Indian J. Pathol. Microbiol., 2023, 66: 3-8

[81] Hong KOet al.. Tumor budding is associated with poor prognosis of oral squamous cell carcinoma and histologically represents an epithelial-mesenchymal transition process. Hum. Pathol., 2018, 80: 123-129

[82] Jensen DHet al.. Molecular profiling of tumour budding implicates TGFβ-mediated epithelial-mesenchymal transition as a therapeutic target in oral squamous cell carcinoma. J. Pathol., 2015, 236: 505-516

[83] Verstappe J, Berx G. A role for partial epithelial-to-mesenchymal transition in enabling stemness in homeostasis and cancer. Semin. Cancer Biol., 2023, 90: 15-28

[84] Jia Det al.. Quantifying cancer epithelial-mesenchymal plasticity and its association with stemness and immune response. J. Clin. Med. Res., 2019, 8: 725

[85] Yu SS, Cirillo N. The molecular markers of cancer stem cells in head and neck tumors. J. Cell. Physiol., 2020, 235: 65-73

[86] Sun Zet al.. Special AT-rich sequence-binding protein-1 participates in the maintenance of breast cancer stem cells through regulation of the Notch signaling pathway and expression of Snail1 and Twist1. Mol. Med. Rep., 2015, 11: 3235-3542

[87] Li Jet al.. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma. Cell Death Dis., 2019, 10 603

[88] Sarubo Met al.. Involvement of TGFBI-TAGLN axis in cancer stem cell property of head and neck squamous cell carcinoma. Sci. Rep., 2024, 14 6767

[89] Tirino Vet al.. TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death Dis., 2013, 4 e620

[90] Kummer Set al.. Feline SCCs of the head and neck display partial epithelial-mesenchymal transition and harbor stem cell-like cancer cells. Pathogens, 2023, 12: 1288

[91] Al Hayek Set al.. Steroid-dependent switch of OvoL/Shavenbaby controls self-renewal versus differentiation of intestinal stem cells. EMBO J., 2021, 40 e104347

[92] Grosse-Wilde Aet al.. Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS One, 2015, 10 e0126522

[93] Papadaki MAet al.. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol. Cancer Ther., 2019, 18: 437-447

[94] Raimondi Cet al.. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system?. Oncoimmunology, 2017, 6 e1315488

[95] Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol., 2017, 14: 611-629

[96] Biddle A, Gammon L, Liang X, Costea DE, Mackenzie IC. Phenotypic plasticity determines cancer stem cell therapeutic resistance in oral squamous cell carcinoma. EBioMedicine, 2016, 4: 138-145

[97] Shi Ret al.. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer. Cell. Signal., 2020, 76: 109810

[98] Shi R-Zet al.. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition. Cell Biol. Int., 2021, 45: 1644-1653

[99] Ingruber J, Dudas J, Sprung S, Lungu B, Mungenast F. Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC. Biomedicines, 2022, 10: 1644-1653

[100] Horny Ket al.. Mesenchymal-epithelial transition in lymph node metastases of oral squamous cell carcinoma is accompanied by ZEB1 expression. J. Transl. Med., 2023, 21 267

[101] Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell, 2019, 24: 65-78

[102] Emprou Cet al.. SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients. Cancer Med., 2018, 7: 3278-3291

[103] Pastushenko Iet al.. Identification of the tumour transition states occurring during EMT. Nature, 2018, 556: 463-468

[104] Puram SVet al.. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell, 2017, 171: 1611-1624.e1624

[105] Simeonov KPet al.. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell, 2021, 39: 1150-1162.e1159

[106] Yang Jet al.. Guidelines and definitions for research on epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol., 2020, 21: 341-352

[107] Kisoda Set al.. Prognostic value of partial EMT-related genes in head and neck squamous cell carcinoma by a bioinformatic analysis. Oral. Dis., 2020, 26: 1149-1156

[108] Wangmo C, Charoen N, Jantharapattana K, Dechaphunkul A, Thongsuksai P. Epithelial-mesenchymal transition predicts survival in oral squamous cell carcinoma. Pathol. Oncol. Res., 2020, 26: 1511-1518

[109] Wen Jet al.. The epithelial-mesenchymal transition phenotype of metastatic lymph nodes impacts the prognosis of esophageal squamous cell carcinoma patients. Oncotarget, 2016, 7: 37581-37588

[110] Sinha D, Saha P, Samanta A, Bishayee A. Emerging concepts of hybrid epithelial-to-mesenchymal transition in cancer progression. Biomolecules, 2020, 10: 1561

[111] Usami Yet al.. Snail-associated epithelial-mesenchymal transition promotes oesophageal squamous cell carcinoma motility and progression. J. Pathol., 2008, 215: 330-339

[112] Pastushenko Iet al.. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature, 2021, 589: 448-455

[113] Parikh ASet al.. Immunohistochemical quantification of partial-EMT in oral cavity squamous cell carcinoma primary tumors is associated with nodal metastasis. Oral. Oncol., 2019, 99: 104458

[114] Xiong HGet al.. Long noncoding RNA MYOSLID promotes invasion and metastasis by modulating the partial epithelial-mesenchymal transition program in head and neck squamous cell carcinoma. J. Exp. Clin. Cancer Res., 2019, 38: 278

[115] Pastushenko I, Blanpain C. EMT transition states during tumor progression and metastasis. Trends Cell Biol., 2019, 29: 212-226

[116] George JT, Jolly MK, Xu S, Somarelli JA, Levine H. Survival outcomes in cancer patients predicted by a partial EMT gene expression scoring metric. Cancer Res., 2017, 77: 6415-6428

[117] Hao Y, Baker D, Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int. J. Mol. Sci., 2019, 20: 2767

[118] Wang X, Eichhorn PJA, Thiery JP. TGF-β, EMT, and resistance to anti-cancer treatment. Semin. Cancer Biol., 2023, 97: 1-11

[119] Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res., 2009, 19: 156-172

[120] Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat. Rev. Clin. Oncol., 2023, 20: 604-623

[121] Szeto GL, Finley SD. Integrative approaches to cancer immunotherapy. Trends Cancer, 2019, 5: 400-410

[122] Cha JH, Chan LC, Song MS, Hung MC. New approaches on cancer immunotherapy. CSH Perspect. Med., 2020, 10: a036863

[123] Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin. Cancer Res., 2019, 25: 5449-5457

[124] Kujan O, Van Schaijik B, Farah CS. Immune checkpoint inhibitors in oral cavity squamous cell carcinoma and oral potentially malignant disorders: a systematic review. Cancers, 2020, 12: 1937

[125] Balança C-Cet al.. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight, 2021, 6 e142513

[126] Hua Y, Dong R, Jin T, Jin Q, Chen X. Anti-PD-1 monoclonal antibody combined with anti-VEGF agent is safe and effective in patients with recurrent/metastatic head and neck squamous cancer as second-line or beyond treatment. Front. Oncol., 2022, 12: 781348

[127] Bourhis M, Palle J, Galy-Fauroux I, Terme M. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. Front. Immunol., 2021, 12: 616837

[128] De Goeje PLet al.. Induction of peripheral effector CD8 T-cell proliferation by combination of paclitaxel, carboplatin, and bevacizumab in non-small cell lung cancer patients. Clin. Cancer Res., 2019, 25: 2219-2227

[129] Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat. Rev. Cancer, 2011, 11: 9-22

[130] Cheng Y, Song Z, Chen J, Tang Z, Wang B. Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods. Heliyon, 2024, 10 e25895

[131] Shayan Get al.. Phase Ib study of immune biomarker modulation with neoadjuvant cetuximab and TLR8 stimulation in head and neck cancer to overcome suppressive myeloid signals. Clin. Cancer Res., 2018, 24: 62-72

[132] Maruyama T, Chen W, Shibata H. TGF-β and cancer immunotherapy. Biol. Pharm. Bull., 2022, 45: 155-161

[133] Gonzalez-Junca Aet al.. Autocrine TGFβ Is a survival factor for monocytes and drives immunosuppressive lineage commitment. Cancer Immunol. Res., 2019, 7: 306-320

[134] Wan YY, Flavell RA. ‘Yin-Yang’ functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol. Rev., 2007, 220: 199-213

[135] Kelley RKet al.. A phase 2 study of galunisertib (TGF-β1 receptor Type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma. Clin. Transl. Gastroenterol., 2019, 10 e00056

[136] Ling Z, Cheng B, Tao X. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: challenges and opportunities. Int. J. Cancer, 2021, 148: 1548-1561

[137] Pomella Set al.. Effects of angiogenic factors on the epithelial-to-mesenchymal transition and their impact on the onset and progression of oral squamous cell carcinoma: an overview. Cells, 2024, 13: 1294

[138] Joseph JP, Harishankar MK, Pillai AA, Devi A. Hypoxia-induced EMT: a review on the mechanism of tumor progression and metastasis in OSCC. Oral. Oncol., 2018, 80: 23-32

[139] Bai Y, Sha J, Kanno T. The role of carcinogenesis-related biomarkers in the Wnt pathway and their effects on epithelial-mesenchymal transition (EMT) in oral squamous cell carcinoma. Cancers, 2020, 12: 555

[140] Shetty SSet al.. Signaling pathways promoting epithelial mesenchymal transition in oral submucous fibrosis and oral squamous cell carcinoma. Jpn Dent. Sci. Rev., 2020, 56: 97-108

Funding

MEXT | Japan Society for the Promotion of Science (JSPS)(22H03288)

MEXT | Japan Science and Technology Agency (JST)(JPMJSP2113)

RIGHTS & PERMISSIONS

The Author(s)